The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes 81240 and 81241: Group 1 Codes Group 2 (200 Codes)
Full Answer
MOLECULAR PATHOLOGY PROCEDURE, LEVEL 9 (EG, ANALYSIS OF >50 EXONS IN A SINGLE GENE BY DNA SEQUENCE ANALYSIS) CPT codes 81162-81167, 81212, 81215, 81216, 81217 are considered medically necessary for the following ICD-10-CM codes:
Correct coding requires that when a panel code is ordered, it should be billed, rather than the individual gene codes. CPT code 81445 or 81450 should be billed when 5 to 50 genes are ordered. CPT code 81455 should be billed when 51 or greater genes are ordered for molecular biomarkers.
The following ICD-10-CM codes support medical necessity and provide coverage for CPT codes 81240 and 81241: It is the provider’s responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim (s) submitted.
1.
This testing is considered investigational and is NOT a Medicare benefit.
NCD - Partial ThromboplastinTime (PTT) (190.16)
Group 1CodeDescription81241F5 (COAGULATION FACTOR V) (EG, HEREDITARY HYPERCOAGULABILITY) GENE ANALYSIS, LEIDEN VARIANT81291MTHFR (5,10-METHYLENETETRAHYDROFOLATE REDUCTASE) (EG, HEREDITARY HYPERCOAGULABILITY) GENE ANALYSIS, COMMON VARIANTS (EG, 677T, 1298C)1 more row
In 2018, Medicare issued a national coverage determination (NCD) providing reimbursement for next-generation sequencing (NGS) tests for beneficiaries with advanced or metastatic cancer and no previous NGS testing.
For CPT Code 81408, level 9 Molecular Pathology Procedures are noncovered. Based on the Centers for Medicare & Medicaid Services (CMS) Program Integrity Manual (100 - 08), this policy addresses the circumstances under which the item or service is reasonable and necessary under the Social Security Act, §1862(a)(1)(A).
The PTT NCD includes in the covered list of ICD-9-CM diagnostic codes code V72. 81 (Pre-operative cardiovascular examination,) code V72. 83 (Other specified pre-operative examination,) and code V72. 84 (Pre-operative examination, unspecified).
1: Abnormal coagulation profile.
The Centers for Medicare & Medicaid Services (CMS) today expanded Medicare coverage for home blood testing of prothrombin time (PT) International Normalized Ratio (INR) to include beneficiaries who are using the drug warfarin, an anticoagulant (blood thinner) medication, for chronic atrial fibrillation or venous ...
Hereditary deficiency of other clotting factors The 2022 edition of ICD-10-CM D68. 2 became effective on October 1, 2021. This is the American ICD-10-CM version of D68.
This testing is considered investigational and is NOT a Medicare benefit.
Acquired coagulation factor deficiency D68. 4 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D68. 4 became effective on October 1, 2021.
CPT code 82270 specifically states that it is used for “colorectal neoplasm screening”; 82272 is used for purposes “other than colorectal neoplasm screening.” Medicare requires code G0328 for a fecal hemoglobin determination by immunoassay when the service is performed for colorectal cancer screening rather than ...
Medicare recognizes the two iFOBT codes based on whether the physician orders the test for colorectal cancer screening (G0328) or for a diagnostic purpose (82274).
A written order from the physician responsible for using the results of the test in the management of the beneficiary's medical condition is required for Medicare coverage of this test. A health care provider gives a fecal occult blood test card to the beneficiary, who takes it home and places stool samples on it.
This test is reported differently for private and Medicare payers. For payers who follow CPT guidelines, report 82274 Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations.
As of October 2015, ICD-9 codes are no longer used for medical coding. Instead, use this equivalent ICD-10-CM code, which is an approximate match to ICD-9 code 812.40:
Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis.
CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
Article Text Article Text This article contains coding and other guidelines that complement the Local Coverage Determination (LCD) for Molecular Pathology Procedures. Specific Coding of Molecular Testing Panels The submission of claims using individual gene CPT codes, when either 5-50 or >50 gene panels are ordered, is considered incorrect coding.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.
The patient’s primary care physician or practitioner, an eligible Medicare provider, must order the screening within the context of a primary care setting.
For HBV screening in pregnant women (CPT codes 86704, 86706, 87340 and 87341) report Z11.59 Encounter for screening for other viral diseases with one of the following diagnosis codes: